Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 901–1,000 of 1,001
Qian (2010) · Molecular Medicine Reports · doi:10.3892/mmr_00000301 · Cited by 13
Zhang, J., Nannapaneni, S., Wang, D., Liu, F., Wang, X., Jin, R., Liu, X., Rahman, M. A., Peng, X., Qian, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19779 · Cited by 14
Millisecond molecular dynamics simulations of KRas-dimer formation and interfaces
Ngo, V. A., & García, A. E. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.04.026 · Cited by 14
El‐hanbuli, H., & Sarie, M. A. A. (2022) · Iranian journal of pathology · doi:10.30699/ijp.2022.550727.2856 · Cited by 13
Masucci, M. T., Motti, M. L., Minopoli, M., Carluccio, G. D., & Carriero, M. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076026 · Cited by 15
“Sorafenib is a small molecular weight inhibitor of RAF kinase, PDGFRA, VEGFR2, VEGFR3, and c-KIT, simultaneously targeting the RAF/MEK/ERK pathway.”
BackgroundSGEF is overexpressed in prostate cancer and contributes to prostate cancer progression
Wang, H., Wu, R., Lan, Y., Wu, F., Li, S., Yali, Z., Li, H., Luo, G., WANG, J., & Zhou, J. (2012) · Oncology Reports · doi:10.3892/or.2012.1917 · Cited by 13
Brotto, K., Malisic, E. J., Cavic, M. R., Krivokuća, A., & Jankovic, R. N. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2469-9 · Cited by 13
Chen, M.-C., Chen, C.-H., Liu, Y.-N., Wang, H.-P., Pan, S., & Teng, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.028 · Cited by 13
“[29–31] As shown in Fig.”
Esposito, M. T. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000195 · Cited by 11
KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan
Awidi, M. A., Ababneh, N. A., Shomaf, M. S., Al-Fararjeh, F., Owaidi, L., AlKhatib, M. A., Tarawneh, B. A., & Awidi, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226473 · Cited by 13
“[7,8] KRAS mutations account for about 85% of all RAS mutations in human cancers, while NRAS mutations account for about 15%.”
BackgroundProximal Protein Interaction Landscape of RAS Paralogs
Béganton, B., Coyaud, É., Laurent, E. M. N., Mangé, A., Jacquemetton, J., Romancer, M. L., Raught, B., & Solassol, J. (2020) · Cancers · doi:10.3390/cancers12113326 · Cited by 14
“KRAS mutations are considered to be responsible for approximately one million deaths per year worldwide [7,8].”
BackgroundKim, K. M., Kim, N. S., Kim, J., Park, J.-S., Yi, J. M., Lee, J. H., & Bang, O. (2013) · Nutrition and Cancer · doi:10.1080/01635581.2013.828082 · Cited by 13
Transcriptional hallmarks of noonan syndrome and noonan‐like syndrome with loose anagen hair
Ferrero, G. B., Picco, G., Baldassarre, G., Flex, E., Isella, C., Cantarella, D., Corà, D., Chiesa, N., Crescenzio, N., Timeus, F. S., et al. (2012) · Human Mutation · doi:10.1002/humu.22026 · Cited by 15
Talin1 regulates endometrial adhesive capacity through the Ras signaling pathway
Chen, S., Liu, B., Li, J., Liao, S., Bi, Y., Huang, W., Yuan, L., Yang, Y., & Qin, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119332 · Cited by 13
Ku70 senses cytosolic DNA and assembles a tumor-suppressive signalosome
Pandey, A., Shen, C. X., Feng, S., Tuipulotu, D. E., Ngo, C., Liu, C., Kurera, M., Mathur, A., Venkataraman, S., Zhang, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adh3409 · Cited by 15
“In addition to the plasma membrane, Ras-ERK signaling has been observed at endosomes, the endoplasmic reticulum, the Golgi apparatus, and the mitochondria ( 60 , 61 ).”
Lee, A. A., Kim, N. H., Alvarez, S. A., Ren, H., DeGrandchamp, J. B., Lew, L. J. N., & Groves, J. T. (2024) · Science Advances · doi:10.1126/sciadv.adi0707 · Cited by 14
Landscape of metabolic alterations and treatment strategies in breast cancer
Wu, X., Tan, X., Bao, Y., Yan, W., & Zhang, Y. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101521 · Cited by 19
“82 Under the influence of growth factors or activated RAS, cells activate mTORC1 through diverse signaling pathways, such as PI3K/AKT and RAF/MEK/ERK.”
El-Chaar, N. N., Piccolo, S., Boucher, K. M., Cohen, A. L., Chang, J. T., Moos, P. J., & Bild, A. H. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.005 · Cited by 13
“Activated RAS can interact with more than 20 effectors to regulate various cellular responses, including cellular proliferation, survival and differentiation (Cox and Der, 2010; Der, 2012; Pylayeva-Gupta et al., 2011; Schubbert et al., 2007).”
Akman, T., Öztop, İ., Baskın, Y., Ünek, İ. T., Demir, N., Ellıdokuz, H., & Yilmaz, A. U. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.148684 · Cited by 13
Spatiotemporal imaging of small GTPases activity in live cells
Voß, S., Krüger, D. M., Koch, O., & Wu, Y. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613999113 · Cited by 13
Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
Sfecci, A., Dupuy, A., Dinulescu, M., Droitcourt, C., Adamski, H., Hadj-Rabia, S., Odent, S., Galibert, M., & Boussemart, L. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.12.012 · Cited by 12
Lim, J. Y., & Kwan, H. Y. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80788 · Cited by 15
“Prenylation is crucial for membrane association and activation of GTPases such as Ras, Rho, cdc42, and GPCRs, all of which are important regulators of cancer [83, 84].”
BackgroundAshktorab, H., Azimi, H., Varma, S. R., Lee, E. L., Laiyemo, A. O., Nickerson, M. L., & Brim, H. (2019) · Oncotarget · doi:10.18632/oncotarget.26721 · Cited by 14
Petersen, C. H., Mahmood, B., Badsted, C., Dahlby, T., Rasmussen, H. B., Hansen, M. B., & Bindslev, N. (2019) · BMC Cancer · doi:10.1186/s12885-019-5833-8 · Cited by 11
Wang, L., Proulx, M.-È., Kim, A. D., Lelarge, V., & McCaffrey, L. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-02178-2 · Cited by 14
Pathogenic signaling in multiple myeloma
Bolomsky, A., & Young, R. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.005 · Cited by 15
The prognostic value of KRAS mutation in locally advanced rectal cancer
Asawa, P., Bakalov, V., Kancharla, P., Abel, S., Chahine, Z., Monga, D. K., Kirichenko, A. V., & Wegner, R. E. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04167-x · Cited by 13
The Zebrafish Model for Liver Carcinogenesis
Gong, Z., Koh, C. H. V., Nguyễn, A. T., Zhan, H., Li, Z., Lam, S. H., Spitsbergen, J. M., Emelyanov, A., & Parinov, S. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6082-5_11 · Cited by 14
“Besides promoting cell proliferation as frequently reported, c-Myc is also shown to induce apoptosis in the mouse endocrine pancreas, suggesting that c-Myc might have distinct functions in different tissues ( Pelengaris et al. 2002 ).”
BackgroundHu, W. M., Yuan, Q., Liu, X., Zhu, H., Sheng-qi, L., & Wang, X. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.12.025 · Cited by 13
A gene signature for gold nanoparticle-exposed human cell lines
Liang, R., Tu, H.-F., Tan, X., Yeh, Y.-S., Chueh, P. J., & Chuang, S. (2014) · Toxicology Research · doi:10.1039/c4tx00181h · Cited by 12
A High-Content Screening Assay for Small-Molecule Modulators of Oncogene-Induced Senescence
Bitler, B. G., Fink, L. S., Wei, Z., Peterson, J. R., & Zhang, R. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113491827 · Cited by 14
Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects
Deenen, M. J., Cats, A., Beijnen, J. H., & Schellens, J. H. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0261 · Cited by 18
Molecular pathology in real time
Ryška, A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9607-3 · Cited by 14
Chao, C., Li, F., Tan, Z., Zhang, W., Yang, Y., & Luo, C. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.11.030 · Cited by 12
Allosteric Activation of GDP-Bound Ras Isoforms by Bisphenol Derivative Plasticisers
Schöpel, M., Shkura, O., Seidel, J., Kock, K., Zhong, X., Löffek, S., Helfrich, I., Bachmann, H. S., Scherkenbeck, J., Herrmann, C., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041133 · Cited by 13
Tang, M., Dong, Z., Guo, P., Zhang, Y., Zhang, X., Guo, K., An, L., Liu, X., & Zhao, P. (2019) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2019.03.011 · Cited by 12
Pre-Testicular, Testicular, and Post-Testicular Causes of Male Infertility
Dimitriadis, F., Adonakis, G. L., Kaponis, A. I., Mamoulakis, C., Takenaka, A., & Sofikitis, N. (2017) · Endocrinology · doi:10.1007/978-3-319-44441-3_33 · Cited by 16
Advances in Cancer Stem Cell Biology
Scatena, R., Giardina, B., & Mordente, A. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0809-3 · Cited by 14
Cetuximab in first line treatment of metastatic colorectal cancer
Barone, C. A., Belisari, A., Ciardiello, F., Mantovani, L. G., D’Angiolella, L. S., Furneri, G., Normanno, N., Piacentini, P., & Pinto, C. (2012) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v13i1s.305 · Cited by 12
Kötting, C., Suveyzdis, Y., Bojja, R. S., Metzler‐Nolte, N., & Gerwert, K. B. (2010) · Applied Spectroscopy · doi:10.1366/000370210792434341 · Cited by 12
Proteomics Analysis Reveals Novel RASSF2 Interaction Partners
Barnoud, T., Wilkey, D. W., Merchant, M. L., Clark, J. A., & Donninger, H. (2016) · Cancers · doi:10.3390/cancers8030037 · Cited by 12
Wu, X., Park, M., Sarbassova, D. A., Ying, H., Lee, M. G., Bhattacharya, R., Ellis, L. M., Peterson, C. B., Hung, M., Lin, H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32658 · Cited by 13
“tract (33%), colorectal (32%), lung (19%), and ovarian (17%) cancers.(2) However, no effective therapies have been developed”
BackgroundTargeting Oncogenes with siRNAs
Heidenreich, O. T. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-547-7_11 · Cited by 12
Erratum: Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. E. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2175 · Cited by 12
Self-citationPTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
Davis, T. B., Yang, M., Wang, H., Lee, C., Yeatman, T. J., & Pledger, W. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27335 · Cited by 11
Vidimar, V., Park, M., Stubbs, C. K., Ingram, N. K., Qiang, W., Zhang, S., Gursel, D., Melnyk, R. A., & Satchell, K. J. F. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0550 · Cited by 10
Molecular docking analysis of KRAS inhibitors for cancer management
Alam, Q. (2023) · Bioinformation · doi:10.6026/97320630019411 · Cited by 13
Xu, C., Chen, G., Yu, B., Sun, B., Zhang, Y., Zhang, M., Yang, Y., Xiao, Y., Cheng, S., Li, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202400023 · Cited by 17
Biarc, J., Gonzalo, P., Mikaélian, I., Fattet, L., Deygas, M., Gillet, G., Lemoine, J., & Rimokh, R. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.05.026 · Cited by 11
Live-Cell Microscopy Reveals Small Molecule Inhibitor Effects on MAPK Pathway Dynamics
Anderson, D. J., Durieux, J., Song, K. W., Alvarado, R., Jackson, P. K., Hatzivassiliou, G., & Ludlam, M. J. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022607 · Cited by 10
Niu, J., Mo, Q., Wang, H., Li, M., Cui, J., Li, Z., & Li, Z. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.109 · Cited by 11
Niu, Y., Yao, X., & Ji, H. (2019) · RSC Advances · doi:10.1039/c9ra01657k · Cited by 11
Kim, J., Jeon, Y. J., Lim, S., Ryu, J., Lee, J.-H., Chang, I. Y., & You, H. J. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04332-0 · Cited by 12
Marini, E., Marino, M., Gionfriddo, G., Maione, F., Pandini, M., Oddo, D., Giorgis, M., Rolando, B., Blua, F., Gastaldi, S., et al. (2022) · Molecules · doi:10.3390/molecules27238513 · Cited by 12
The Role of MicroRNAs in Development of Endometrial Cancer: A Literature Review
Indumati, S., Birajdar, A., Gaurav, G., Nehakumari, S., & Nishant, V. (2023) · Journal of Reproduction & Infertility · doi:10.18502/jri.v24i3.13271 · Cited by 15
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
Caiola, E., Rulli, E., Fruscio, R., Buda, A. A., Broggini, M., & Marabese, M. (2012) · Europe PMC (PubMed Central) · Cited by 11
MicroRNA‐Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer
Sharma, S. B., & Ruppert, J. M. (2015) · Drug Development Research · doi:10.1002/ddr.21270 · Cited by 11
The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer.
Hsieh, S., Kuo, S.-N., Zheng, Y.-H., Tsai, M.-H., Lin, Y., & Lin, J.-H. (2013) · PubMed · Cited by 12
Zhang, S., Hwaiz, R. A., Rahman, M., Herwald, H., & Thorlacius, H. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.03.029 · Cited by 11
“Downstream signaling of Ras includes three major pathways culminating in the activation of ERK 1/2, Akt and RalA proteins (Schubbert et al., 2007).”
BackgroundXavier, C. P. R., & Pereira‐Wilson, C. (2015) · PharmaNutrition · doi:10.1016/j.phanu.2015.11.002 · Cited by 13
Oncogenes and Signal Transduction
Grumolato, L., & Aaronson, S. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00002-0 · Cited by 11
IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA
Komatsu, Y., Derwish, L., & Hirasawa, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160529 · Cited by 14
Robles-Remacho, A., Luque-González, M. A., González-Casín, R. A., Cano‐Cortés, V., López‐Delgado, F. J., Guardia-Monteagudo, J. J., Fara, M. A., Sanchez-Martin, R. M., & Díaz‐Mochon, J. J. (2021) · Talanta · doi:10.1016/j.talanta.2021.122092 · Cited by 11
“The appearance of point mutations in the KRAS gene triggers cancer development, and represents around 20–30% of all mutations found in human tumours, predominantly adenocarcinomas (pancreatic, colorectal, lung, ovarian, cervical, and biliary tract adenocarcinomas) [2,28,29].”
BackgroundMethodOxidative Stress and Drug Resistance in Cancer
Trachootham, D., Zhang, W., & Huang, P. (2009) · Springer eBooks · doi:10.1007/978-0-387-89445-4_7 · Cited by 17
Ryu, S., Kim, K. H., Kim, H., Kim, M.-H., Kim, N., Kang, Y., Hyun, J. W., Seo, H.-J., Jun, J., & You, H. J. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01626.x · Cited by 11
Takemura, T., Nakamura, S., Yokota, D., Hirano, I., Ono, T., Shigeno, K., Fujisawa, S., & Ohnishi, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075788 · Cited by 12
Nkembo, A. T., Amissah, F., Ntantie, E., Poku, R. A., Salako, O. O., Ikpatt, O. F., & Lamango, N. S. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666190325144636 · Cited by 12
Cognition and emotion in adults with Noonan syndrome. A neuropsychological perspective
Wingbermühle, P. A. M. (2013) · Radboud Repository (Radboud University) · Cited by 74
Nosan, G., Bertok, S., Vesel, S., Yntema, H. G., & Paro‐Panjan, D. (2013) · Croatian Medical Journal · doi:10.3325/cmj.2013.54.574 · Cited by 10
Goecks, J., El‐Rayes, B. F., Maithel, S. K., Khoury, H. J., Taylor, J., & Rossi, M. R. (2015) · Cancer Medicine · doi:10.1002/cam4.360 · Cited by 14
Comparison of KRAS Mutation Tests in Colorectal Cancer Patients
Hançer, V. S., Büyükdoğan, M., Türkmen, İ., Başsüllü, N., Altuğ, T., Küçükkaya, R. D., Doğusoy, G., & Demir, G. (2011) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0027 · Cited by 10
Sanctis, G. D., Spinelli, M., Vanoni, M., & Sacco, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163790 · Cited by 11
Regulation of the Small GTPase Ras and Its Relevance to Human Disease
Kulhanek, K. R., Roose, J. P., & Rubio, I. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1190-6_2 · Cited by 10
Ras Multimers on the Membrane: Many Ways for a Heart-to-Heart Conversation
Özdemir, E. S., Koester, A. M., & Nan, X. (2022) · Genes · doi:10.3390/genes13020219 · Cited by 11
“Mutations in the RAS genes, commonly at the G12, G13, and Q61 residues, or loss of Ras GAPs such as NF1, impair GTP hydrolysis to result in upregulated Ras-GTP, ultimately leading to oncogenic transformation and other, pathologic conditions [17,18].”
BackgroundXu, Y., Zhu, C., Lu, Y., Yang, S., Fang, J., & Jiang, Z. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105436 · Cited by 11
Jakubauskas, A., & Griškevičius, L. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.4.620 · Cited by 10
Síndrome de Noonan: do fenótipo à terapêutica com hormônio de crescimento
Malaquias, A. C., Ferreira, L. V., Souza, S. C. A. L., Arnhold, I. J. P., Mendonca, B. B., & Jorge, A. A. L. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000500012 · Cited by 10
Apoptosis Induction by 13‐Acetoxyrolandrolide through the Mitochondrial Intrinsic Pathway
Acuña, U. M., Matthew, S., Pan, L., Kinghorn, A. D., Swanson, S. M., & de Blanco, E. J. C. (2013) · Phytotherapy Research · doi:10.1002/ptr.5091 · Cited by 10
Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population.
Nanda, M. S., Sameer, A. S., Syeed, N., Shah, Z. A., Murtaza, I., Siddiqi, M. A., & Ali, A. (2010) · Urology journal./Urology jornal. · Cited by 11
Nanami, T., Shimada, H., Yajima, S., Oshima, Y., Matsushita, K., Nomura, F., Nagata, M., Tagawa, M., Otsuka, S., Kuwajima, A., et al. (2015) · Esophagus · doi:10.1007/s10388-015-0510-8 · Cited by 12
Chen, Z., Xie, W., Acheampong, D. O., Xu, M., He, H., Yang, M., Li, C., Luo, C., Wang, M., & Zhang, J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1121344 · Cited by 11
Overexpression of Insulin-like Growth Factor-1 Receptor Is Associated With Penile Cancer Progression
Ball, M. W., Bezerra, S. M., Chaux, A., Faraj, S. F., González-Roibón, N., Munari, E., Sharma, R. B., Bivalacqua, T. J., Netto, G. J., & Burnett, A. L. “. (2016) · Urology · doi:10.1016/j.urology.2016.02.006 · Cited by 10
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib
Gamba, S., Čamaj, P., Heinemann, V., Laubender, R. P., Wang, Y., Zhao, Y., Stintzing, S., Giessen, C. A., Boeck, S. H., Haertl, C., et al. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000196 · Cited by 10
New Gene Profiling in Determination of Breast Cancer Recurrence and Prognosis in Iranian Women
Poorhosseini, S. M., Hashemi, M. M., Olyaei, N. A., Izadi, A., Moslemi, E., Ravesh, Z., Hashemi‐Gorji, F., Kheiri, H. R., & Yassaee, V. R. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.s3.155 · Cited by 10
Schäfer, C., Mohan, A. S., Burford, W. B., Driscoll, M., Ludlow, A. T., Wright, W. E., Shay, J. W., & Danuser, G. M. (2016) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/2/3/035004 · Cited by 10
ERas is constitutively expressed in full term placenta of pregnant cows
Roperto, S., Russo, V., Urraro, C., Restucci, B., Corrado, F., Falco, F. D., & Roperto, F. P. (2017) · Theriogenology · doi:10.1016/j.theriogenology.2017.07.047 · Cited by 10
The multikinase inhibitor RXDX-105 is effective against neuroblastomain vitroandin vivo
Flynn, S. M., Lesperance, J., Macias, A., Phanhthilath, N., Paul, M. R., Kim, J. W., Tamayo, P., & Zage, P. E. (2019) · Oncotarget · doi:10.18632/oncotarget.27259 · Cited by 10
RNF141 interacts with KRAS to promote colorectal cancer progression
Zhang, J., Jiang, X., Yin, J., Dou, S., Xie, X., Liu, T., Wang, Y., Wang, S., Zhou, X., Zhang, D., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01877-4 · Cited by 12
Rontauroli, S., Carretta, C., Parenti, S., Bertesi, M., & Manfredini, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315256 · Cited by 12
“These variants activate growth signals by reducing intrinsic GTP hydrolysis and promoting resistance to GTPase-activating proteins (GAPs) [52].”
BackgroundMechanistic modeling to investigate signaling by oncogenic Ras mutants
Stites, E. C., & Ravichandran, K. S. (2011) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.156 · Cited by 10
Assessing the clinical significance of tumor markers in common neoplasms
Beketić-Orešković, L., Maric, P., Ozretic, P., Oreskovic, D., Ajdukovic, M., & Levanat, S. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e566 · Cited by 14
Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma
Palomba, G., Cossu, A., Paliogiannis, P., Pazzola, A., Baldino, G., Scartozzi, M., Ionta, M. T., Ortu, S., Capelli, F., Lanzillo, A., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4798 · Cited by 10
Garde, J., Lewintre, E. J., Gil-Raga, M., Evgenyeva, E., Escalante, S. M., Llombart‐Cussac, A., & Camps, C. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1149 · Cited by 11
Castagna, J., Clerc, J., Dupond, A.-S., & Laresche, C. (2017) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2017.06.008 · Cited by 11
Mues, M., Karra, L., Romero–Moya, D., Wandler, A. M., Hangauer, M. J., Ksionda, O., Thus, Y. J., Lindenbergh, M. F., Shannon, K., McManus, M. T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.045 · Cited by 11
“KRAS-specific inhibitors, oncogenic Ras is an exceedingly difficult therapeutic target (Cox et al., 2014; Ostrem and Shokat, 2016; Schubbert et al., 2007; Simanshu et al., 2017).”
BackgroundSelf-citationUveal melanoma modeling in mice and zebrafish
van den Bosch, Q. C. C., de Klein, A., Verdijk, R. M., Kılıç, E., & Brosens, E. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189055 · Cited by 11
NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer
Yang, G., Ding, C., Yang, X. Y., Jiang, J., He, S., Shao, Y., Zhang, E., Fan, X., Zhou, X., Huang, L., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.07.035 · Cited by 10
“Mutation of RAS impairs the intrinsic GTPase activity and thus turns on RAF-mediated signaling [9].”
Yang, C., Li, H.-X., Gan, H., Shuai, X., Dong, C., Wang, W. J., Lin, D., & Zhong, B. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.01.015 · Cited by 10
Direkte Modulation von Aktivität und Funktion kleiner GTPasen
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie · doi:10.1002/ange.201504357 · Cited by 9
Xing, Y., & Hogge, D. E. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.03.003 · Cited by 9
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.